Evidence map›Paper›PMID 36817042›Full record

ArticleOncology letters2023

Evaluation of

Nikolay Kalitin, Galina Dudina, Natalia Kostritsa, Anastasiya Sivirinova, Aida Karamysheva

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Nikolay KalitinLaboratory of Tumor Cell Genetics, N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia.
Galina DudinaDepartment of Oncohematology, A.S. Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia.
Natalia KostritsaFaculty of Fundamental Medicine, M.V. Lomonosov Moscow State University, 119234 Moscow, Russia.
Anastasiya SivirinovaFaculty of Fundamental Medicine, M.V. Lomonosov Moscow State University, 119234 Moscow, Russia.
Aida KaramyshevaLaboratory of Tumor Cell Genetics, N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia.
Lomonosov Moscow State University · RURussian Cancer Research Center NN Blokhin · RUMoscow Clinical Scientific Center · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular endothelial growth factors (VEGFs) are angiogenic factors playing a key role in tumor development. VEGFs are produced by different normal and tumor cells, including platelets, lymphocytes and mononuclear cells of peripheral blood.

Indexed as

gene expressionmyelodysplastic syndromerisk factorVEGF-AVEGFR1

Identifiers

PMID36817042
PMCPMC9932006
OpenAlexW4318196875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.